Worth reading
90Important
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Details of issuance or disposal
32nd and 35th stock acquisition rights with exercise price adjustment clauses issued by third-party allotment
Amount of funds to be raised
32nd: ¥727 million in funds raised to date; estimated net proceeds are Not disclosed. 35th: ¥1,006 million expected to be raised; estimated net proceeds are Not disclosed.
Specific use of funds
MRX-4TZT: costs of the Phase 2 clinical trial for a treatment for spastic paralysis (tizanidine transdermal patch), including preparation costs such as manufacturing the investigational drugAmount ¥140 million (32nd; ¥0 million utilized through the end of July 2026) / Scheduled timing of expenditures April 2025 to June 2027
Costs of preparing for the launch of MRX-5LBT “Bondlido” and maintaining its marketing authorizationAmount ¥260 million (32nd; ¥35 million utilized through the end of July 2026) / Scheduled timing of expenditures October 2025 to October 2026
Research and development expenses focused on formulation development, and working capitalAmount ¥327 million (32nd; ¥327 million utilized through the end of July 2026) / Scheduled timing of expenditures August 2025 to April 2026
MRX-4TZT: costs of the Phase 2 clinical trial for a treatment for spastic paralysis (tizanidine transdermal patch)Amount ¥330 million (35th; ¥0 million utilized through the end of July 2026) / Scheduled timing of expenditures June 2026 to June 2027
Costs of maintaining Bondlido's marketing authorizationAmount ¥100 million (35th; ¥0 million utilized through the end of July 2026) / Scheduled timing of expenditures November 2026 to December 2027
Research and development expenses focused on formulation development, and working capitalAmount ¥576 million (35th; ¥0 million utilized through the end of July 2026) / Scheduled timing of expenditures June 2026 to August 2027
Terms of the stock acquisition rights
Exercise price
The filing states that these are stock acquisition rights with exercise price adjustment clauses, but the initial exercise price and floor price are Not disclosed.
| Item | Details |
|---|---|
| Type of issuance or disposal | 32nd and 35th stock acquisition rights with exercise price adjustment clauses issued by third-party allotment |
| Amount of funds to be raised | 32nd: ¥727 million in funds raised to date; estimated net proceeds are Not disclosed. 35th: ¥1,006 million expected to be raised; estimated net proceeds are Not disclosed. |
| Specific use of funds | Details MRX-4TZT: costs of the Phase 2 clinical trial for a treatment for spastic paralysis (tizanidine transdermal patch), including preparation costs such as manufacturing the investigational drug / Amount ¥140 million (32nd; ¥0 million utilized through the end of July 2026) / Scheduled timing of expenditures April 2025 to June 2027, Details Costs of preparing for the launch of MRX-5LBT “Bondlido” and maintaining its marketing authorization / Amount ¥260 million (32nd; ¥35 million utilized through the end of July 2026) / Scheduled timing of expenditures October 2025 to October 2026, Details Research and development expenses focused on formulation development, and working capital / Amount ¥327 million (32nd; ¥327 million utilized through the end of July 2026) / Scheduled timing of expenditures August 2025 to April 2026, Details MRX-4TZT: costs of the Phase 2 clinical trial for a treatment for spastic paralysis (tizanidine transdermal patch) / Amount ¥330 million (35th; ¥0 million utilized through the end of July 2026) / Scheduled timing of expenditures June 2026 to June 2027, Details Costs of maintaining Bondlido's marketing authorization / Amount ¥100 million (35th; ¥0 million utilized through the end of July 2026) / Scheduled timing of expenditures November 2026 to December 2027, Details Research and development expenses focused on formulation development, and working capital / Amount ¥576 million (35th; ¥0 million utilized through the end of July 2026) / Scheduled timing of expenditures June 2026 to August 2027 |
| Exercise price | The filing states that these are stock acquisition rights with exercise price adjustment clauses, but the initial exercise price and floor price are Not disclosed. |
Items this document does not state (24)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueEstimated issuance expensesPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Patient enrollment in the MRX-4TZT Phase 2 clinical trial is progressing more slowly than initially expected.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.